Interneuron Pharmaceuticals Inc. (IPIC) advised investors in its 10Q filing that the New England Journal of Medicine soon will publish a study that will show a higher incidence of a lung disorder called primary pulmonary hypertension (PPH) in patients using anorectic drugs, which include IPIC's Redux dexfenfluramine.

PPH is an extremely rare, but fatal, complication associated with anorectic drugs